Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Expects 62 Percent Rise in Q4 Revenues

NEW YORK (GenomeWeb) – WaferGen Bio-systems announced today that it expects to report a 62 percent rise in fourth quarter revenues while meeting its full-year revenue guidance.

For the three-month period ended Dec. 31, WaferGen's revenues are expected to be $3.9 million compared with $2.4 million in the same period the year before. The company said its revenues for 2016 are expected to be approximately $10.7 million, in line with previous guidance of $10 million to $12 million.

WaferGen said that it ended 2016 with about $4.5 million in cash, including a $2.5 million deposit received from Takara Bio USA Holdings pursuant to the companies' merger agreement announced last year.

Under the terms of the deal, WaferGen's purchase price would be based on a multiple between one and three-and-a-half times of its full-year 2016 revenues, with the multiple capped at three-and-a-half times if those revenues exceed $9 million. Based on the company's revenue projections, the merger is valued at roughly $37.5 million including the deposit. It is expected to close by next month.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.